BRIDGEWATER, N.J., Nov. 26, 2019 /PRNewswire/ -- Insmed Incorporated
(Nasdaq: INSM), a global biopharmaceutical company on a mission to
transform the lives of patients with serious and rare diseases,
today announced that management will present at the following
investor conferences:
- The Evercore ISI HealthCONx Conference in Boston on Tuesday,
December 3, 2019 at 1:35 p.m.
ET
- The 41st NASDAQ Investor Conference in London on Wednesday,
December 4, 2019 at 9:15 a.m.
GMT
Each presentation will be webcast live and can be accessed by
visiting the investor relations section of the company's website at
www.insmed.com. Each webcast will be archived for a period of 30
days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product,
ARIKAYCE® (amikacin liposome inhalation
suspension), is the first and only therapy approved in the United States for the treatment of
refractory Mycobacterium avium complex (MAC) lung disease as
part of a combination antibacterial drug regimen for adult patients
with limited or no alternative treatment options. MAC lung disease
is a chronic, debilitating condition that can cause severe and
permanent lung damage. Insmed's earlier-stage clinical pipeline
includes INS1007, a novel oral reversible inhibitor of dipeptidyl
peptidase 1 with therapeutic potential in non-cystic fibrosis
bronchiectasis and other inflammatory diseases, and INS1009, an
inhaled formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension. For more information,
visit www.insmed.com.
Contact:
Blaine Davis
Head of Investor Relations and Corporate Communications
Insmed Incorporated
(732) 487-7310
blaine.davis@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-present-at-two-december-conferences-300964942.html
SOURCE Insmed Incorporated